LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

LLY

962.69

-1.73%↓

JNJ

221.49

-0.61%↓

ABBV

200.33

-2.6%↓

UNH

373.71

+1.54%↑

AZN

182.39

-0.45%↓

Strona główna・Stock List・Roivant Sciences Ltd

Roivant Sciences Ltd

Closed

SectorHealthcare

28.31 -0.88

Buy Sell

Overview

Share price change

24h

Current

Min

27.84

Max

28.71

Key metrics
By Trading Economics
Income	-200M -314M
Sales	428K 2M
Profit margin	-15,692.896
Employees	750
EBITDA	-132M -290M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+20.4% upside

Market Stats
By TradingEconomics
Market Cap	5B 20B
Previous open	29.19
Previous close	28.31

News Sentiment

By Acuity

67%

33%

312 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

11 / 11.18 Support & Resistance

Roivant Sciences Ltd Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 maj 2026, 23:58 UTC

Earnings

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 maj 2026, 22:57 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 maj 2026, 23:52 UTC

Earnings

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 maj 2026, 23:45 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 maj 2026, 23:39 UTC

Market Talk

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 maj 2026, 23:28 UTC

Market Talk

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 maj 2026, 23:11 UTC

Earnings

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 maj 2026, 23:06 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 maj 2026, 23:05 UTC

Earnings

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 maj 2026, 23:04 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 maj 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 maj 2026, 23:03 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 maj 2026, 23:02 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 maj 2026, 23:00 UTC

Market Talk

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 maj 2026, 22:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 maj 2026, 22:45 UTC

Market Talk

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 maj 2026, 22:42 UTC

Earnings

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 maj 2026, 22:33 UTC

Earnings

Acquisitions, Mergers, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 maj 2026, 22:32 UTC

Earnings

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 maj 2026, 22:31 UTC

Earnings

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 maj 2026, 22:31 UTC

Earnings

Macquarie: 68% of FY Income From International >MQG.AU

7 maj 2026, 22:30 UTC

Earnings

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 maj 2026, 22:30 UTC

Earnings

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 maj 2026, 22:29 UTC

Earnings

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 maj 2026, 22:28 UTC

Earnings

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 maj 2026, 22:28 UTC

Earnings

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 maj 2026, 22:27 UTC

Earnings

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 maj 2026, 22:27 UTC

Earnings

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 maj 2026, 22:26 UTC

Earnings

Macquarie to End Share Buyback Extended in November>MQG.AU

7 maj 2026, 22:25 UTC

Earnings

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Peer Comparison

Price change

Roivant Sciences Ltd Forecast

Price Target

By TipRanks

20.4% upside

12 Months Forecast

Average 34.7 USD 20.4%

High 41 USD

Low 29 USD

Based on 10 Wall Street analysts offering 12 month price targets forRoivant Sciences Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to Roivant Sciences Ltd - Dist in the past 3 months.

Technical Score

By Trading Central

11 / 11.18Support & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentiment

By Acuity

312 / 347 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.